GLP-1 drugs are rewriting the obesity conversation. The metabolic story is bigger than the weight

This stopped being a weight loss story about two years ago

In 2021, semaglutide produced an average 15 percent reduction in body weight in the STEP trials. Extraordinary by historical drug standards. In 2022, tirzepatide posted a 22 percent increase. The weight story dominated coverage. Meanwhile, elsewhere in the clinical literature, something more significant was accumulating.

The SELECT trial in 2023 found that semaglutide reduced major cardiovascular events by 20 percent in people without diabetes. The SURMOUNT-OSA trials in 2024: tirzepatide reduced the apnea-hypopnea index (AHI) by 55 to 63 percent in people with OSA, producing the first-ever FDA approval of a drug specifically for sleep apnea. Active trials are now underway for Alzheimer’s disease, chronic kidney disease, metabolic-associated steatohepatitis, and alcohol use disorder.

The drug class is developing a profile that looks less like an obesity medication and more like a systemic metabolic intervention. The conversation about who should use these drugs is a medical one, not a shortcut discussion.

How GLP-1 receptors actually work

GLP-1 (glucagon-like peptide-1) is a hormone produced in the gut after eating. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and signals satiety to the hypothalamus. GLP-1 receptors are not limited to the gut and pancreas. They are distributed throughout the brain, heart, kidneys, and vasculature.

In people with obesity, the GLP-1 signal is dysregulated. The receptor response is blunted. The body produces fewer satiety signals per calorie consumed and clears them faster. GLP-1 receptor agonists work by binding to the same receptors with a much longer half-life, restoring a signal that the body’s own system is failing to generate adequately.

Tirzepatide adds a second mechanism by activating GIP (glucose-dependent insulinotropic polypeptide) receptors, which amplifies its metabolic effects and accounts for its greater efficacy compared with semaglutide alone. This dual agonism is what puts tirzepatide firmly in the peptide and emerging therapy category rather than simply the weight loss drug category.

The expanding indication list

Obstructive sleep apnea. Tirzepatide received FDA approval for OSA in December 2024. The SURMOUNT-OSA trials showed AHI reductions of 55 to 63 percent, comparable to CPAP in mild-to-moderate cases. For the large population who are CPAP-intolerant, this opens a meaningful treatment pathway for the first time.

Cardiovascular disease. The SELECT trial established a 20 percent reduction in major adverse cardiovascular events with semaglutide in non-diabetic adults with overweight or obesity. The cardiovascular benefit appears to extend beyond weight loss through direct effects on cardiac GLP-1 receptors, anti-inflammatory pathways, and blood pressure reduction.

Alzheimer’s and neurodegeneration. GLP-1 receptors in the brain are expressed in brain regions implicated in neurodegeneration. Observational data from diabetic populations already show lower Alzheimer’s incidence in GLP-1 users versus other antidiabetic drugs. The HOPE and EVOKE trials will report full results in 2025 to 2026.

Alcohol and substance use. An unexpected finding across patient-reported data and animal studies: GLP-1 receptor agonism reduces reward-driven behavior, including alcohol consumption and smoking. The mechanism appears to involve modulation of the GLP-1 receptor in dopaminergic reward pathways. Phase 2 trials for alcohol use disorder are underway.

Protecting muscle mass during treatment

GLP-1 drugs significantly reduce appetite. Without deliberate effort, protein intake drops alongside total calories, accelerating muscle loss alongside fat loss. Research on GLP-1 therapy consistently shows that without active muscle-preservation strategies, a higher proportion of weight loss comes from lean mass than is desirable. The number on the scale moves in the right direction. The composition of what was lost is a separate question.

Target 1.2 to 1.6 grams of protein per kilogram of body weight daily throughout treatment. Add resistance training at least twice per week. Creatine monohydrate at 5 grams daily helps preserve lean mass during caloric restriction, backed by decades of safety data. Garden of Life Sport Protein is a clean, high-quality option that makes the daily protein target achievable on low-appetite days when solid food feels unappealing.

Micronutrient deficiency is a secondary risk due to the substantial reduction in food intake. A comprehensive multivitamin fills the gap without requiring additional meal planning. Electrolyte loss is also common during the first weeks of treatment, particularly of sodium. An electrolyte powder without added sugar addresses this without the glucose spike of most sports drinks.

The Livium recipe

Tool. If eligible (BMI above 30, or above 27 with a weight-related condition such as OSA, hypertension, or prediabetes), talk to a physician specifically about tirzepatide or semaglutide. This is a clinically appropriate conversation, not a shortcut. Request a baseline metabolic panel, including fasting insulin, HbA1c, liver enzymes, and kidney function, before starting. A CGM worn during the first 8 to 12 weeks tracks the metabolic correction in real time and tells you whether the intervention is working before the scale reflects it.

Behavior. Protein 1.2 to 1.6 g/kg daily throughout treatment, resistance training twice per week minimum, and creatine 5 g daily from day one. GLP-1 therapy handles the metabolic correction. The exercise and protein protocol determines whether the loss is fat or muscle. These are not optional additions to the treatment. They are part of it.

Threshold. After 12 weeks, a 5 percent reduction in body weight is the clinical response threshold. Fasting insulin, triglycerides, and blood pressure typically show measurable improvement before the scale does. Rerun the metabolic panel at 12 weeks. If fasting insulin drops below 7 mcIU/mL, the correction is taking hold.

GLP-1 indications: approved, in trials, and under investigation

Source: Livium editorial synthesis based on published FDA approvals and ClinicalTrials.gov active trial database, June 2026.

Plan of action

• If BMI is above 27 with a weight-related condition, book a physician consultation specifically about GLP-1 therapy. Ask about tirzepatide and semaglutide by name. Many GPs are still defaulting to older medications for weight management.
• Request a baseline metabolic panel before starting: fasting insulin, HbA1c, liver enzymes, and kidney function. You need a before picture to measure the after.
• Have creatine and a clean protein powder ready before the first dose. The muscle preservation protocol starts on day one, not after the weight starts moving.
• If OSA is part of the picture, get a home sleep test before or alongside starting GLP-1 therapy. Tirzepatide is now approved for OSA, and the two conditions often improve together.